Intellia Therapeutics Inc

NTLA: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
@#nLOCK|Z#lLOCK|?c!!wZb

Intellia: FDA Lifts Phase 3 Hold for ATTR-CM Trial; Positive Long-Term Data for Lonvo-Z

The US Food and Drug Administration lifted Intellia's clinical hold on its gene therapy trial for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) treated with nex-z after previous reports of serious liver toxicity led to a patient death in the trial.

Sponsor Center